Recombinant Human CD48 protein (Myc Tag, His Tag)

ED50

66-264 ng/mL

Species

Human

Purity

>90 %, SDS-PAGE

GeneID

962

Accession

P09326

Cat No : Eg32086

Print datasheet

Synonyms

BCM1, BLAST, BLAST1, CD48, MEM 102, SLAMF2



Technical Specifications

Purity >90 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Immobilized Human CD48 (Myc tag, His tag) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD244 (hFc tag, Myc tag, His tag) with a linear range of 66-264 ng/mL.
Source HEK293-derived Human CD48 protein Gln27-Ser220 (Accession# P09326) with a Myc tag and a His tag at the C-terminus.
Predicted Molecular Mass 24.8 kDa
SDS-PAGE 38-50 kDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Signaling lymphocytic activation molecule family 2 (SLAMF2, CD48) is an adhesion and costimulatory molecule expressed constitutively on most hematopoietic cells, particularly in antigen presenting cells (APC). CD48 is expressed on all the hematopoietic cells, both in human and mice, except for murine neutrophils and long term-HSC. as a number of GpI receptors do, also CD48 exists as both a membrane bound (mCD48) and a soluble (sCD48) form. CD48 can have activating roles on T cells, antigen presenting cells and granulocytes, by binding to CD2 or bacterial FimH, and through cell intrinsic effects. Interactions between CD48 and its high affinity ligand CD244 are more complex, with both stimulatory and inhibitory outcomes. CD48 expression is increased in autoimmunity and allergy diseases, and anti-CD48 monoclonal antibodies have been shown to attenuate experimental autoimmune encephalomyelitis.

References:

1.Cunyi Zou. et al. (2019). Onco Targets Ther. 12:4181-4193. 2.Shannon L McArdel. et al. (2016). Clin Immunol. 164:10-20. 3.Hadas Pahima. et al. (2019). Clin Immunol. 204:64-68. 4.Shannon L McArdel. et al. (2016). J Immunol. 197(8):3038-3048.